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The adipose tissue in the human body is there 
for the best, the bad and the worse!
Paraphrased from Charles Lapiere 
and Erik Maquoi (1) 
Published on 1 December 1994 issue of Nature (2), the Jef-
frey Friedman’s discovery “gave leptin in the beginning” of 
the endocrine saga of adipose tissue. Onwards, studies on 
this tissue have enjoyed an explosive growth that conceptual-
ized a novel field of research, adipobiology (3). Arguably, in 
the heart of adipobiology and adipopharmacology are stud-
ies focusing on the pathogenesis, prevention and therapy of 
cardiometabolic diseases (CMD) including atherosclerosis, 
hypertension, obesity, type 2 diabetes, metabolic syndrome 
(global cardiometabolic risk), and lipodystrophies. 
 The 2nd International Symposium on Adipobiology and 
Adipopharmacology (ISAA) was organized by the Bulgarian 
Society for Cell Biology. Scientists from 15 countries pre-
sented 34 state-of-the-science (SOS) lectures. 
Gema Frühbeck (Pamplona, Spain) highlighted the sig-
nificance of adipokines represented by a large number of sig-
naling proteins, e.g. pro- and anti-inflammatory interleukins, 
also leptin, adiponectin, resistin, tumor necrosis factor-α, 
renin, angiotensin II, and the “newcomers” retinol-binding 
protein-4, angiopoietin-like protein-2 (Angpl-2) and Angpl-4 
(fasting-induced adipose factor), visfatin, vaspin, pigment 
epithelium-derived factor, apelin, chemerin, adrenomedullin, 
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lipocalin-2, and nerve growth factor (NGF) (4). She also in-
troduced caveolins and aquaporin-7 (AQP-7) into the patho-
genesis of CMD. 
Caroline Pond (Milton Keynes, UK) presented her SOS 
on paracrine interactions between perinodal white adipose 
tissue and lymph nodes. She demonstrated that adipocytes 
associated with lymphoid structures are specialised to supply 
fatty acids, and possibly other precursors, to lymphoid cells.  
Such mechanisms emancipate the immune system from fluc-
tuations in the composition and quantity of dietary lipids and 
are particularly important during immune responses, when 
perinodal adipose tissue remote from the site of immune 
stimulation as well as that around the locally stimulated 
nodes are activated.  Caroline Pond also provided evidence 
that defective perinodal adipose tissue may be central to 
Crohn’s disease (5). 
Harold Sacks (Memphis, Tennessee, USA) presented re-
sults about paracrine secretion of adipokines by epicardial 
adipose tissue and its significance for cardiovascular disease 
(6). His talk as well as that of Caroline Pond stressed the 
relevance of adipotopography in pursuing a hidden Homo 
obesus (7), a phenotype of TOFI (thin outside, fat inside), 
a term coined initially by Jimmy Bell (Imperial College, 
Hammersmith Hospital, London, UK), to emphasize that we 
cannot not rely only on BMI and other “classical” anthro-
pometric measurements when imaging techniques (ECHO, 
MRI, PET) currently are able to provide visual information 
on external (outside) and internal (inside) accumulation of 
adipose tissue. 
Stuart Wood (Liverpool, UK) explained that adipose en-
largement and adipocyte hypertrophy generate a hypoxic 
environment which trigger the secretion of proinflammatory 
adipokines which, in turn, may be further involved in the de-
velopment of obesity and associated diseases (8). 
The “ongoing story” of leptin (9) was described by: (i) 
Arieh Gertler (Rehovot, Israel) focusing on leptin receptor 
antagonists’ anti-inflammatory and anti-fibrotic potentials in 
autoimmune diseases and liver cirrhosis, also cachesia in can-
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cer and AIDS (10), (ii) Morris Karmazyn (London, Ontario, 
Canada) paving the molecular pathway of leptin-induced car-
diomyocyte hypertrophy, demonstrating a significant activa-
tion of the RhoA/ROCK pathway and an increased polymeri-
zation of actin, showing that leptin receptor antagonists may 
improve heart function in experimental model of myocardial 
infarction (11), (iii) Jerzy Beltowski and Andrzej Marciniak 
(Lublin, Poland) presenting data of leptin’s thrombogenic 
and atherogenic effect, revealing that leptin (a) increases 
thromboxane A2 formation (12), and (b) inhibits paraoxonase 
1 activity, thus enhancing protein homocysteinylation - these 
events are prevented by (a) the PPAR-γ agonist rosiglitazone, 
and (b) a synthetic liver X receptor agonist, and (iv) Esin 
Gurel (Ankara, Turkey) showing leptin-induced changes in 
erythrocyte rheology after oxidative stress. 
Johan Renes (Maastricht, The Netherlands) highlighted 
the present adipoproteome map, revealing that proteomic 
technologies are fascinating tools for the identification of 
new adipokines and organelle-specific proteins (13). 
Mariyana Hristova (Varna, Bulgaria) presented ongoing 
results about their hypothesis of metabotrophic potentials 
of NGF and brain-derived neurotrophic factor (BDNF) as 
related to CMD (14), reporting effects of the anti-diabetic 
drug metformin and nonsteroid anti-inflammatory drugs on 
serum NGF and BDNF levels in patients with mild and with 
advanced stage of metabolic syndrome. Yu Nofuji (Fuku-
oka, Japan) presented findings showing that physical activ-
ity altered serum BDNF levels (15) as well as appreciated 
the recent data of BDNF as a myokine, that is, a cytokine 
secreted by skeletal muscles (16). Marcia Hiriart’s (Mexico 
city, Mexico) pioneering data on NGF secretion by pancre-
atic beta cells (17) were extended in her SOS lecture on the 
involvement of peripancreatic adipose tissue in sucrose-in-
duced metabolic syndrome in rats. Marco Fiore and Mauro 
Ceccanti (Rome, Italy) demonstrated that chronic prenatal 
exposure of mice to ethanol, but not red wine, causes memory 
deficit expressed by reduced presence of brain NGF, BDNF 
and choline acetyltransferase reactivity in the offspring (18). 
Dragan Djuric (Belgrade, Serbia) focused on the role of 
folic acid and homocysteine, which is also “secreted” by 
adipose tissue (19), in coronary artery functions evaluated 
by coronary flow and oxidative stress biomarkers. Bilge Peh-
livanoglu (Ankara, Turkey) associated obesity with immune 
cell responses to stress. Hiroshi Yamamoto (Kanazawa, Ja-
pan) looked for the “enemies and friends within” the mecha-
nisms of diabetic angiopathy. He portrayed the AGE-RAGE-
esRAGE system, that is, advanced glycation end-products 
and their receptors, and an endogenous secreted splice variant 
coding for a decoy form of RAGE, respectively (20). Neşe 
Tunçel (Eskişehir, Turkey) implicated white- and brown adi-
pose tissue-derived nitric oxide and associated mast cells in 
cold stress-mediated vascular contractility in rats (21), refer-
ring also to the recent challenge in brown adipobiology (22). 
Sukhinder Cheema (St. John’s, Newfoundland, Canada) 
highlighted the paradigm of nutrition-related developmental 
programming as related to the prevention of CMD, showing 
that a maternal high-fat diet alters the lipid metabolism, in-
cluding hepatic LDL receptor expression, of their adult male 
offspring (23). Vladmila Bojanić (Niš, Serbia) reviewed data 
showing the effects of placenta- and breast milk-derived lep-
tin on mother’s and offspring’s health, the so-called leptin-
mediated metabolic programming (see 10). Collectively, 
CMD prevention should start during in utero and suckling 
life of the human. Likewise, Harpal Buttar (Ottawa, Ontario, 
Canada) advocated that “prevention is better than cure”. 
There is an overwhelming evidence that the Mediterranean-
type diets which are high in fibre, low in saturated fat and 
glycemic load are associated with the decreased prevalence 
of metabolic syndrome and diabetes mellitus as well as im-
proved lipid homeostasis and reduced risk of CMD. Of note, 
Harpal Buttar mentioned recent data of Yuji Matsuzawa’s 
group demonstrating that smoking cessation is associated 
with increased plasma levels of adiponectin, an anti-ather-
ogenic and anti-diabetic adipokine (24). Richelle McCul-
lough (Winnipeg, Manitoba, Canada) presented findings 
demonstrating that flaxseed is an excellent source of alpha 
linolenic acid (ALA), which is stored in adipose tissue, and 
that dietary flaxseed inhibits cardiac arrhythmias and reduces 
atherosclerosis (25). 
Gorana Rančić (Niš, Serbia) implicated adipose-pine-
al network in the chronobiology of CMD. Luigi Aloe and 
George Chaldakov raised a hypothesis of adipose tissue as 
a third brain (26) - this sophisticated tissue is a source of 
and target for a variety of hypothalamus-pituitary hormones, 
releasing factors, neuropeptides and neurotrophic factors, 
which play a pivotal role in lipid, glucose and energy home-
ostasis as well as learning, memory and other neural func-
tions. This may open a novel field of research, neuroadipolo-
gy, which may contribute to further study of the pathogenesis 
of CMD (26,27; for leptin’s neurotrophic action, see 10). 
 As we started this Report, “the adipose tissue in the human 
body is there for the best, the bad and the worse”. “The best”, 
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because adipose tissue produces (i) anti-obesity, anti-inflam-
matory and anti-atherogenic factors such as adiponectin, 
brain-derived-neurotrophic factor (BDNF), inteleukin-10, 
IL-1 receptor antagonist, (ii) vascular relaxants such as ad-
ipose-derived relaxing factors, nitric oxide (NO), hydrogen 
sulfide (H2S), and adiponectin , and (iii) neurotrophic fac-
tors such as NGF, BDNF, ciliary neurotrophic factor, leptin, 
and NPY and other neuropeptides. “The bad”, because adi-
pose tissue produces pro-inflammatory factors such as tumor 
necrosis factor-α and various cytokines and chemokines with 
such an activity. “The worse”, because adipose tissue when 
(i) disappear resulting in lipodystrophies, and (ii) accumulate 
around vital organs in the human body leading to various car-
diometabolic diseases.
Altogether, adipose tissue may be a crossroad of CMD 
and neurodegenerative diseases. Further progress in adipo-
biology and adipopharmacology holds much promise for 
understanding how to walk on that road. Finally, all partici-
pants broadcasted the signal of “SOS for Homo obesus”, to 
hopefully reach politicians and businessmen, and make them 
altruistic to science and human health. 
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